Pulmonary mucormycosis
Conditions
Interventions
Liposomal Amphotericin B (AmBisome) Plus Isavuconazole:Liposomal Amphotericin B (AmBisome) Plus Isavuconazole
Liposomal Amphotericin B (AmBisome):Liposomal Amphotericin B (AmBisome)
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 years or older diagnosed with pulmonary mucormycosis; 2.Individuals with Probable or proved PM, as indicated by clinical and radiological findings;
Exclusion criteria
Exclusion criteria: 1. Patients with a history of pulmonary mucormycosis (PM) who have previously been treated with amphotericin B for a duration exceeding 5 days. 2. Patients who have documented allergies to azoles or amphotericin B regimens; 3. Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin levels exceeding five times the upper limit of normal (ULN). 4. Patients with irreversible heart or liver failure, or those experiencing massive, fatal hemoptysis. 5. Patients currently receiving extracorporeal membrane oxygenation (ECMO) treatment. 6. Pregnant or breastfeeding individuals. 7. Patients with individual reasons that may prevent them from completing the treatment protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of overall favourable responses at D28; | — |
Secondary
| Measure | Time frame |
|---|---|
| 84 day-mortality;168 day-mortality;adverse event; | — |
Countries
China
Contacts
Public ContactCao Bin
China-Japan Friendship Hospital
Outcome results
None listed